...
  • About
    • Overview
    • Leadership
    • Board Of Directors
    • Our Culture
    • Gallery
  • Product Portfolio
    • Technology
    • Pipeline
    • ZTLido®
    • Elyxyb®
    • Gloperba®
    • Expanded Access Policy
  • Partners
  • Science
    • Medical information U.S.
    • Publications
  • Investors
    • Investors Overview
    • News & Events
    • Presentations
    • SEC Filings
    • Governance
    • Analyst Coverage
    • Contact Investor Relations
    • Stock Information
    • FAQs
  • Join Our Team
  • Contact Us
    • Contact Us
    • Locations
Shopping cart close
Scilex Holding Scilex Holding
  • About
    • Overview
    • Leadership
    • Board Of Directors
    • Our Culture
    • Gallery
  • Product Portfolio
    • Technology
    • Pipeline
    • ZTLido®
    • Elyxyb®
    • Gloperba®
    • Expanded Access Policy
  • Partners
  • Science
    • Medical information U.S.
    • Publications
  • Investors
    • Investors Overview
    • News & Events
    • Presentations
    • SEC Filings
    • Governance
    • Analyst Coverage
    • Contact Investor Relations
    • Stock Information
    • FAQs
  • Join Our Team
  • Contact Us
    • Contact Us
    • Locations

Posts by Jitendra

Home » Articles Posted by Jitendra (Page 6)
15 Feb
SEC FIlings

Prospectus [Rule 424(b)(3)]

  • February 15, 2023
  • Posted by Jitendra

Read more

15 Feb
SEC FIlings

Prospectus [Rule 424(b)(3)]

  • February 15, 2023
  • Posted by Jitendra

Read more

15 Feb
SEC FIlings

Prospectus [Rule 424(b)(3)]

  • February 15, 2023
  • Posted by Jitendra

Read more

12 Feb
Press Release

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., acquires rights to FDA-Approved ELYXYBTM in the U.S. and Canada for the acute treatment of migraine

  • February 12, 2023
  • Posted by Jitendra
ELYXYBTM is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1   The acute migraine drug market size...

Read more

06 Feb
SEC FIlings

Current report

  • February 6, 2023
  • Posted by Jitendra

Read more

04 Feb
Press Release

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Record and Meeting Dates for its first Annual Meeting of Stockholders

  • February 4, 2023
  • Posted by Jitendra
PALO ALTO, February 4, 2023 /Newswire/ -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), an innovative revenue-generating company focused...

Read more

03 Feb
SEC FIlings

Prospectus [Rule 424(b)(3)]

  • February 3, 2023
  • Posted by Jitendra

Read more

03 Feb
SEC FIlings

Prospectus [Rule 424(b)(3)]

  • February 3, 2023
  • Posted by Jitendra

Read more

03 Feb
SEC FIlings

Prospectus [Rule 424(b)(3)]

  • February 3, 2023
  • Posted by Jitendra

Read more

02 Feb
SEC FIlings

Current report

  • February 2, 2023
  • Posted by Jitendra

Read more

«‹45678›»
Close
Recent Posts
  • Nasdaq_Gloperba03
    Gloperba Launch – Nasdaq-2024
    July 10, 2024 No Comments
  • A randomized, placebo-controlled trial of long-acting dexamethasone viscous gel delivered by transforaminal injection for lumbosacral radicular pain
    June 14, 2024 No Comments
  • Gout Awareness Day – May 22
    May 20, 2024 No Comments
  • Decreased Opioid Utilization with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis
    March 14, 2024 No Comments
  • Retrospective Claims Analysis of Decreased Healthcare Visits with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch
    March 14, 2024 No Comments

scilex-holding-logo-white

Terms of Use  Privacy Policy  Contact

  • Follow us on Facebook
  • Follow us on LinkedIn
  • Contact us by email

©2024 Scilex Holding All Rights Reserved
Scilex Holding Company is the owner of Scilex Pharmaceuticals and Semnur Pharmaceuticals

Scroll To Top Sidebar
We use cookies to improve your experience on our website. By browsing this website, you agree to our use of cookies.
Accept More info